OPKO Health, Inc. (NASDAQ:OPK) Files An 8-K Financial Statements and Exhibits
ITEM 9.01.
Financial Statements and Exhibits.
|
ExhibitNo. |
Description |
|
23.1 |
Consent of Ernst & Young LLP |
|
99.1 |
Revised Items of OPKO Health, Inc. 2017 Form 10-K for the fiscal year ended December 31, 2017 |
|
101.INS |
XBRL Instance Document |
|
101.SCH |
XBRL Taxonomy Extension Schema Document |
|
101.CAL |
XBRL Taxonomy Extension Calculation Linkbase Document |
|
101.DEF |
XBRL Taxonomy Extension Definition Linkbase Document |
|
101.LAB |
XBRL Taxonomy Extension Label Linkbase Document |
|
101.PRE |
XBRL Taxonomy Extension Presentation Linkbase Document |
Exhibit List
Opko Health, Inc. Exhibit
EX-23.1 2 ex231consent.htm EXHIBIT 23.1 Exhibit Exhibit 23.1Consent of Independent Registered Certified Public Accounting FirmWe consent to the incorporation by reference in the following Registration Statements: 1.Registration Statement (Form S-8 No. 333-211209) pertaining to the 2016 Equity Incentive Plan of OPKO Health,…
To view the full exhibit click here
About OPKO Health, Inc. (NASDAQ:OPK)
OPKO Health, Inc. (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations. The Company’s diagnostics business includes Bio-Reference Laboratories (Bio-Reference), which is a clinical laboratory with a genetic testing business, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. Its pharmaceutical business includes OPKO Biologics, which features hGH-CTP, a once-weekly human growth hormone injection (in Phase III and partnered with Pfizer), and a longer acting Factor VIIa drug for hemophilia (Phase IIa). In addition to its pharmaceutical and diagnostic development programs, it owns pharmaceutical platforms in Ireland, Chile, Spain and Mexico.